Signadori Bio Secures €11 Million Seed Round To Advance Next-Generation Solid Tumour Platform

The round included participation from Taiho Ventures, alongside existing investors Sofinnova Partners and Invivo Partners.

The company will use the funds to advance its lead programme, SiB-2101, toward candidate nomination, further develop its in vivo monocyte engineering platform, and expand its scientific and operational teams.

Founded by Jean-Luc Perfettini and Nathalie Chaput, and based on research from Gustave Roussy, Signadori Bio is developing off-the-shelf immunotherapies that engineer monocytes directly in the body.

Read Also - Spain’s Humara Raises €1.2M To Expand AI Platform For Waste And Recycling Plants

Its approach aims to harness the innate immune system to overcome tumour-induced immunosuppression and improve treatment outcomes for solid cancers.

"This financing represents an important milestone for Signadori Bio as we continue to build on our promising preclinical data and advance our platform toward the clinic. Our approach to in vivo engineering of monocytes has the potential to unlock a new class of immunotherapies that are more accessible, scalable, and effective for patients with solid tumours. We are delighted to welcome Taiho Ventures alongside our existing investors, Sofinnova Partners and Invivo Partners." Dr. Selwyn Ho, Chief Executive Officer, Signadori Bio